

This newsletter summarises final decisions from HTA bodies around the world from July 2023.

These decisions have been categorised into one of four groups. You can click on the category you are interested in to jump to that section.

[Pharmacological Technologies](#)

[Non-pharmacological Technologies](#)

[Diagnostic Tests](#)

[Other Guidance](#)

Within each section the reports have been grouped according to clinical speciality. On the section contents page, there are shortcuts to each clinical speciality and specific report. All tiles are hyperlinked to the report file or to the HTA website.

Here we list a key for the decisions made by the HTA bodies for the reports listed in this newsletter.



Approved - This is where the reporting document states that the technology has been approved.



Not approved - This is where the reporting document states that the technology has not been approved.



Terminated - The report was terminated, additional details are provided under the icon.



Excluded - The report was excluded because it is covered by another HTA body in that country.



Unclear - This is where documentation cannot be translated or it is unclear on the reporting outcome.



Note - This entry includes a note from the report relating to the technology.



Evidence review - This is for reports that do not report a decision but summarises the evidence for the technology.

Pharmacological Technologies



Blood

- [Andexanet alfa - Australia](#)
- [Concizumab - Australia](#)
- [Luspatercept - Germany](#)
- [Ropeginterferon alfa-2b - Scotland](#)



Cancer


- [Tafasitamab - Australia](#)
- [Selpercatinib - Australia](#)
- [Sotorasib - France](#)
- [Dabrafenib-trametinib - France](#)
- [Nivolumab - France](#)
- [Tisagenlecleucel - France](#)
- [Epcoritamab - France](#)
- [Glofitamab - France](#)
- [Axicabtagene ciloleucel - France](#)
- [Sacituzumab govitecan - France](#)
- [Olaparib - England](#)
- [Lorlatinib - England](#)
- [Selpercatinib - England](#)
- [Olaparib - Germany](#)
- [Durvalumab - Germany](#)
- [Belantamab-mafodotin - Germany](#)
- [Durvalumab - Germany](#)
- [Tremelimumab - Germany](#)
- [Tremelimumab - Germany](#)
- [Durvalumab - Germany](#)
- [Darolutamide - Germany](#)
- [Lutetiumvipivotidetetraxetan - Germany](#)
- [Olaparib - Germany](#)
- [Lutetiumvipivotidetetraxetan - Germany](#)

- [Olaparib - Germany](#)
- [Ibrutinib - Germany](#)
- [Trastuzumab deruxtecan - Germany](#)
- [Ibrutinib - Germany](#)
- [Polatuzumab vedotin - Scotland](#)
- [Apalutamide - Scotland](#)
- [Azacitidine - Scotland](#)
- [Avacopan - Australia](#)

- [Dulaglutide - Germany](#)
- [Dupilumab - Germany](#)

- [Imlifidase - Australia](#)


- [Lonafarnib - France](#)
- [Afamelanotide - England](#)
- [Avalglucosidase alfa - Scotland](#)



Cardiovascular



Endocrine



Gastrointestinal



Genitourinary



Metabolic
/Genetic

Pharmacological Technologies




Neurology

- Riluzole - Canada
- Efgartigimod alfa - France
- Ravulizumab - France
- Rimegepant - England
- Lasmiditan - Germany



Respiratory

- Beclometasone dipropionate - Wales



Skin

- Dupilumab - Germany
- Dupilumab - Germany
- Deucravacitinib - Germany

Other

- Semaglutide - England
- Pitolisant - Germany
- Belumosudil - Scotland

Non-pharmacological Technologies




Blood

- Equine anti-human T-lymphocyte immunoglobulin - France



Cancer

- Electroporation - England



Musculoskeletal

- Platelet-rich plasma injections - Canada
- Platelet-rich plasma injections - Canada
- Platelet-rich plasma injections - Canada
- Polyurethane scaffold - South Korea
- Craniocaudal expandable titanium implants - South Korea
- Bone marrow aspirate - South Korea
- Perioperative normothermia intervention - Canada



Surgery

Other


- Electrostimulation - Canada
- Extracorporeal shock wave therapy - South Korea

Diagnostic Tests



Cancer

- [AI screening of CT scans - England](#)



Cardiovascular

- [KardiaMobile - England](#)



Infection

- [Point-of-care Test - Canada](#)



Musculoskeletal

- [X-ray imaging system - Ireland](#)
- [Tomography - South Korea](#)

Other Guidance



Blood

- Secondary treatment in chronic immune thrombocytopenia - Canada



Cancer

- Trastuzumab deruxtecan - Germany
- Tremelimumab-durvalumab - Austria
- Trifluridine/tipiracil - Austria
- Sacituzumab govitecan - Austria
- Trastuzumab - Switzerland

Other

- Cannabis - United States

Pharmacological Technologies




Blood

Australia



Andexanet alfa

Andexanet alfa for  patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
ATC V03AB38

Population:
Adult




12 July 2023

Australia



Concizumab

Concizumab is for  where prophylaxis is required to prevent or reduce the frequency of bleeding in patients who have haemophilia B (congenital factor IX [FIX] deficiency) with FIX inhibitors.
ATC

Population:
Other
At least 12 years




14 July 2023

Germany



Luspatercept

For patients with anemia associated with non-transfusion-dependent beta-thalassemia. 

IQWiG A23-20

Population:
Adult




03 July 2023

Scotland



Ropeginterferon
alfa-2b

Monotherapy for the treatment of polycythaemia vera without symptomatic splenomegaly. 

SMC2563

Population:
Adult



10 July 2023

Pharmacological Technologies



Cancer

Australia



Tafasitamab

Tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
ATC L01FX12

Population:
Adult



For provisional registration

03 July 2023

Australia



Selpercatinib

Selpercatinib for the treatment of patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).

ATC L01EX22


Population:
Adult



For provisional registration

14 July 2023

France



Sotorasib


Sotorasib as monotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, whose disease has progressed after at least one line of prior systemic therapy.
HAS AP190

Population:
Adult



03 July 2023

France



Dabrafenib-trametinib

Combination therapy for patients with glioma.

HAS AP210

Population:
Children
1 year or older




03 July 2023

Pharmacological Technologies




Cancer

France



Nivolumab

Population:
Other Adults and adolescents aged 12 and over
07 July 2023



Nivolumab for monotherapy in the adjuvant treatment of patients with stage IIB or IIC melanoma who have undergone complete resection.

HAS AP202




France



Tisagenlecleucel

Population:
Adult
07 July 2023




Treatment of patients with follicular lymphoma after at least two lines of treatment.

HAS AP208




France



Epcoritamab

Population:
Adult
20 July 2023



Treatment of patients with refractory or relapsed diffuse large B-cell lymphoma (DLBCL), after at least two lines of systemic treatment.

HAS AP218




France



Glofitamab

Population:
Adult
20 July 2023



Treatment of patients with refractory or relapsed diffuse large B-cell lymphoma (DLBCL), after at least two lines of systemic treatment.

HAS AP230



Pharmacological Technologies



Cancer


France



Axicabtagene ciloleucel

Population:
Adult

27 July 2023



Treatment of patients with refractory or relapsed diffuse large B-cell lymphoma within 12 months after the end of line and eligible for salvage chemotherapy.

HAS AP221



APPROVED


France



Sacituzumab govitecan

Population:
Adult

27 July 2023




Treatment as monotherapy of patients with unresectable or metastatic triple-negative breast cancer, who have previously received two lines of treatment systemic or more.

HAS AP209



APPROVED


England



Olaparib


Population:
Unknown

05 July 2023



Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy.

NICE TA908



APPROVED

Under commercial arrangement


England



Lorlatinib

Population:
Unknown

12 July 2023



Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer.

NICE TA909



NOT APPROVED

Pharmacological Technologies



Cancer

England



Selpercatinib

Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer.

NICE TA911



Under commercial arrangement

Population:
Adult

26 July 2023

Germany



Olaparib

Treatment of patients with advanced BRCA1/2-mutant, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

IQWiG A23-32



Population:
Adult

03 July 2023

Germany



Durvalumab

First-line treatment of unresectable or metastatic biliary tumors in adults in combination with cisplatin and gemcitabine.

IQWiG A23-26



Population:
Unknown

03 July 2023

Germany



Belantamab-mafodotin

Monotherapy for the treatment of multiple myeloma in patients who have received four therapies and whose disease is refractory to at least one proteasome inhibitor.

IQWiG G23-05



Population:
Unknown

03 July 2023

Pharmacological Technologies



Cancer


Germany



Durvalumab

Population:
Adult

03 July 2023




Treatment for patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR mutations or ALK-positive mutations.

IQWiG A23-31



NOT APPROVED


Germany



Tremelimumab

Population:
Adult

03 July 2023




Treatment for patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR mutations or ALK-positive mutations.

IQWiG A23-29



NOT APPROVED


Germany



Tremelimumab

Population:
Adult

03 July 2023



For first-line treatment of advanced or unresectable hepatocellular carcinoma.

IQWiG A23-30



NOT APPROVED


Germany



Durvalumab

Population:
Adult

03 July 2023



For first-line treatment of advanced or unresectable hepatocellular carcinoma.

IQWiG A23-27



NOT APPROVED

Pharmacological Technologies



Cancer


Germany



Darolutamide

Population:
Adult

03 July 2023



Treatment for patients with metastatic hormone-sensitive prostate cancer.

IQWiG A23-21




Germany



Lutetiumvivotidete traxetan


Population:
Adult

06 July 2023



Combination therapy for patient with progressive prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

IQWiG A23-46



Under special arrangement


Germany



Olaparib


Population:
Adult

06 July 2023



For patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

IQWiG A23-03



Under special arrangement


Germany



Lutetiumvivotidete traxetan


Population:
Adult

06 July 2023



Combination therapy for patient with progressive prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

IQWiG A23-01



Under special arrangement

Pharmacological Technologies



Cancer


<p>Germany</p>  <p>Olaparib</p> <p>Population: Adult</p> <p>06 July 2023</p>	<p>For patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.</p> <p><i>IQWiG A23-47</i></p> <p> APPROVED</p> <p>Under special arrangement</p>	<p>Germany</p>  <p>Ibrutinib</p> <p>Population: Adult</p> <p>20 July 2023</p>	<p>Treatment for patients with chronic lymphocytic leukemia who have not been previously treated.</p> <p><i>IQWiG A23-54</i></p> <p> NOT APPROVED</p>
<p>Germany</p>  <p>Trastuzumab deruxtecan</p> <p>Population: Adult</p> <p>20 July 2023</p>	<p>Patients with unresectable or metastatic HER2-low breast cancer who have previously received chemotherapy.</p> <p><i>IQWiG A23-07</i></p> <p> APPROVED</p>	<p>Germany</p>  <p>Ibrutinib</p> <p>Population: Adult</p> <p>20 July 2023</p>	<p>Patients with chronic lymphocytic leukemia who have not been previously treated.</p> <p><i>IQWiG A23-04</i></p> <p> NOT APPROVED</p>

Pharmacological Technologies



Cancer


Scotland



Polatuzumab vedotin

Population:
Adult

10 July 2023




Combination with bendamustine and rituximab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

SMC2524




Scotland



Apalutamide

Population:
Adult

10 July 2023




Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.

SMC2579




Scotland



Azacitidine

Population:
Adult

10 July 2023




Maintenance therapy in patients with acute myeloid leukaemia.

SMC2533



Pharmacological Technologies



Cardiovascular



Endocrine

Australia



Avacopan

Avacopan, in combination with a rituximab or cyclophosphamide based regimen, for the treatment of patients with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
ATC L04AA59



Population:
Adult

28 July 2023

Germany



Dulaglutide

Management of type 2 diabetes mellitus as a supplement to diet and exercise.


IQWiG A23-28



Population:
Children
10 to 17 years

03 July 2023

Pharmacological Technologies



Gastrointestinal



Genitourinary

Germany



Dupilumab

For treatment of eosinophilic oesophagitis.

IQWiG A23-23



Population:
Other Adults and adolescents aged 12 and over
03 July 2023

Australia



Imlifidase

Imlifidase for the desensitisation treatment of highly sensitised kidney transplant candidates prior to kidney transplantation from a donor against whom there is a positive cross-match.
ATC L04AA41



Population:
Adult

21 July 2023

For provisional registration

Pharmacological Technologies



Metabolic/Genetic

France



Lonafarnib

Treatment of patients with a genetically confirmed diagnosis of Hutchinson-Gilford syndrome.

HAS AP232



Population:
Other
Aged 12 months and over

27 July 2023

England



Afamelanotide

Afamelanotide for treating erythropoietic protoporphyria.

NICE HST27



Population:
Unknown

26 July 2023

Scotland



Avalglucosidase alfa

Long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α -glucosidase deficiency).

SMC2546



Population:
Unknown

10 July 2023

Pharmacological Technologies



Neurology

Canada



Riluzole

Riluzole treatment for amyotrophic lateral sclerosis treatment.

CADTH RC1487-000



Population:
Unknown

07 July 2023

France



Efgartigimod alfa


Combination with standard treatment in patients with generalized autoimmune myasthenia gravis presenting with anti-acetylcholine receptor antibodies (aRach) remaining symptomatic.
HAS AP223



Population:
Adult

27 July 2023

France



Ravulizumab

Treatment of acquired generalized myasthenia gravis (AG) in symptomatic patients with refractory generalized autoimmune myasthenia gravis.

HAS AP207



Population:
Adult

27 July 2023

England



Rimegepant

Rimegepant for preventing migraine.

NICE TA906



Population:
Adult

05 July 2023

Pharmacological Technologies



Neurology



Respiratory

Germany



Lasmiditan

Patients who require acute treatment during the headache phase of migraine attacks with or without aura.

IQWiG A23-35



Population:
Adult

17 July 2023

Wales



Beclometasone
dipropionate

For the prophylactic management of mild, moderate, or severe asthma.

AWMSG 5294




Population:
Other
Adults or
children

04 July 2023

Generic product

Pharmacological Technologies



Skin

Germany



Dupilumab

For patients with severe atopic dermatitis who are candidates for systemic therapy.

IQWiG A23-25



Population:
Children
6 month to 5 years

03 July 2023

Germany



Dupilumab

For treatment of moderate to severe nodular prurigo in patients who are candidates for systemic therapy.

IQWiG A23-24



Population:
Adult

03 July 2023

Germany



Deucravacitinib

Treatment for patients with moderate to severe plaque psoriasis.

IQWiG A23-34



Population:
Adult

17 July 2023

Pharmacological Technologies

Other


England



Semaglutide

Population:
Children
12 to 17 years

13 July 2023

 Semaglutide for managing overweight and obesity.

NICE TA910



Evidence not submitted


Germany



Pitolisant

Population:
Adult

03 July 2023

 For the treatment of narcolepsy with or without cataplexy.

IQWiG G23-06




Scotland



Belumosudil

Population:
Other
Patient aged 12 and above

10 July 2023

 Treatment of patients with chronic graft-versus-host disease (cGvHD) who have received at least two prior lines of systemic therapy.

SMC2583



Non-pharmacological Technologies



Blood



Cancer

France



Equine anti-human
T-lymphocyte
immunoglobulin

Immunosuppressive
treatment for the
treatment of moderate
to severe forms of
acquired bone marrow
depression in those that
cannot receive
hematopoietic stem cell
transplantation (HSCT).

HAS AP233



Population:
Other
Adult and children
aged 2 years or
above

20 July 2023

England



Electroporation

Irreversible
electroporation for
treating prostate cancer.

NICE IPG768




Population:
Unknown

05 July 2023

Under special
arrangement

Non-pharmacological Technologies



Musculoskeletal

Canada



Platelet-rich plasma injections for chronic tendinopathies in the lower extremities.

CADTH RC1486-000

Platelet-rich plasma injections

Population:
Adult

10 July 2023



Canada



Platelet-rich plasma injections for lower back pain.

CADTH RC1485-000

Platelet-rich plasma injections

Population:
Adult

31 July 2023



Canada



Platelet-rich plasma injections for chronic tendinopathies in the upper extremities.

CADTH RC1491-000

Platelet-rich plasma injections

Population:
Adult

31 July 2023



South Korea



In patients with meniscal defect, applying implantation of polyurethane scaffold on partial meniscal treatment.

NECA HTA-2023-37


Polyurethane scaffold

Population:
Unknown

05 July 2023



Non-pharmacological Technologies



Musculoskeletal



Surgery

South Korea



Craniocaudal expandable titanium implants

Population:
Unknown

27 July 2023

Percutaneous augmentation of craniocaudal expandable titanium implants for vertebral compression fracture.

NECA HTA-2023-38



Canada



Perioperative normothermia intervention

Population:
Other
Birthing parents

25 July 2023

Perioperative normothermia interventions to prevent caesarean section surgical site infection.

CADTH RB1673-000



South Korea



Bone marrow aspirate

Population:
Unknown

27 July 2023

Bone Marrow Aspirate Concentrate Application for Knee Osteoarthritis.

NECA HTA-2023-39



Non-pharmacological Technologies

Other

Canada



Electrostimulation

Electrostimulation device for the management of wounds.

CADTH RC1489-000



Population:
Unknown

17 July 2023

South Korea



Extracorporeal shock wave therapy

Low-intensity extracorporeal shock wave therapy for non-inflammatory chronic pelvic pain syndrome.

NECA HTA-2023-35




Population:
Unknown

05 July 2023

Diagnostic Tests



Cancer



Cardiovascular

England



AI screening of CT scans

AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images.

NICE DG55



Potential

Population:
Unknown

05 July 2023

England



KardiaMobile

KardiaMobile for detecting atrial fibrillation.

NICE MTG64



Population:
Unknown

25 July 2023

Reintroduced following
DTAC approval

Diagnostic Tests



Infection

Canada




Point-of-care Test

Population:
Other
Birthing parents and
newborns

13 July 2023

Point-of-care HIV and
syphilis screening in
prenatal care.

CADTH RC1490-000



Musculoskeletal

Ireland



X-ray imaging
system

Population:
Other
Adult and children

10 July 2023

A slot-scanning,
biplanar, digital X-ray
imaging system for the
evaluation and
monitoring of
orthopaedic conditions.

HIQA



South Korea



Tomography

Population:
Unknown

27 July 2023

Ga-68 Edotreotide
(DOTA-TOC) Positron
Emission
Tomography/Positron
Emission Tomography-
Computed Tomography
for Tumor-induced
Osteomalacia.

NECA HTA-2023-40



Other Guidance



Blood

Canada



Secondary treatment
in chronic immune
thrombocytopenia

Population:
Adult

06 July 2023

Evidence review of the
treatment of patients
with chronic immune
thrombocytopenia after
failure of first-line
therapies.

CADTH HT0035-000



Cancer

Germany



Trastuzumab
deruxtecan

Population:
Adult

20 July 2023

For the treatment of
patients with breast
cancer.

IQWiG A23-52



Austria



Tremelimumab-
durvalumab

Population:
Adult

26 July 2023

First-line treatment of
patients with metastatic
NSCLC with no
sensitising EGFR
mutations or ALK
positive mutations.

AIHTA 135



Other Guidance



Cancer

Austria



Trifluridine/tipiracil

Combination with bevacizumab for the treatment of patients with metastatic CRC who have received two prior anticancer treatment regimens

AIHTA 136



Population:
Adult

26 July 2023

Austria



Sacituzumab govitecan

Monotherapy for the treatment of patients with unresectable or metastatic hormone receptor positive (HR+), human epidermal growth receptor 2 negative (HER2-) breast cancer.

AIHTA 137



Population:
Adult

26 July 2023

Switzerland



Trastuzumab

Treatment duration of trastuzumab in HER2-positive early breast cancer.

FOPH



Population:
Unknown

18 July 2023

Other Guidance

Other

United States



Cannabis

Population:
Unknown

27 July 2023



Cannabis and other
plant-based treatments
for chronic pain.

AHRQ



About Us

Crystallise provides an innovative approach to identify and synthesise information, using AI to automate processes and assist our experts to produce deliverables that provide real value to clients.

Our team of researchers, medical writers and copy-editors deliver strategically-relevant and comprehensive written reports as well as visually informative summary slide decks, to suit internal business development, market access, journal publication and health technology assessment submissions.

REVIEWS

Systematic Literature Reviews
Global Value Dossiers
Narrative Reviews
Rapid Reviews
Targeted Reviews

HEALTH ECONOMICS

Return on Investment
Network Meta-Analysis
Budgetary Impact Analysis
Cost-effectiveness Analysis

ACTUARIAL

Risk Management
Pricing & Reserving

MODELLING

Mortality and Morbidity Modelling
Synthetic Sample Generation
Infectious Disease Modelling

[To provide feedback on the HTAngel newsletter, click here.](#)

[To unsubscribe, click here.](#)

Registered address

17 High Street,
Stanford-le-Hope,
Essex, SS17 0HD
+44 (0)1375 517878

Company No: 7980921

Data Protection Act Registration Number: Z3363643

Websites:

www.crystallise.com

www.heoro.com

www.evidencemapper.co.uk